We are thrilled to announce two groundbreaking funding achievements emerging right before the Christmas holidays!
Dr. Elham Sharifikolouei Secures Prestigious FIS Grant for 4D-REVIVE
Dr. Elham Sharifikolouei, a member of our research group, has been awarded €1.327 million through the Fondo Italiano di Scienza (FIS) to lead the 4D-REVIVE project. This significant grant, backed by the Italian Ministry of University and Research (MUR), supports fundamental, high-risk, high-gain research projects.
The 4D-REVIVE project addresses the global challenge of myocardial infarction (MI) with the development of a multifunctional cardiac patch. Utilizing advanced 4D bioprinting, this cutting-edge solution aims to:
- Rejuvenate dormant cardiomyocytes,
- Regenerate cardiac tissue, and
- Mitigate arrhythmia.
By merging innovative technologies such as shape-memory metallic glass nanowires and advanced hydrogels, 4D-REVIVE promises minimally invasive deployment and enhanced cardiac recovery, potentially revolutionizing heart attack treatments and improving the quality of life for millions.
Dr. Sharifikolouei’s work paves the way for transformative advancements in cardiovascular medicine, marking her tenure as an assistant professor at the University of Piemonte Orientale (UPO) with an inspiring beginning.
Horizon Europe Funds INJECTHEAL for Chronic Wound Healing
Our consortium, coordinated by Prof. Lia Rimondini at UPO, has been awarded €7.33 million under the Horizon Europe Innovation Action program for the INJECTHEAL project. Chronic wounds, affecting over 305 million people worldwide, present a critical healthcare challenge. INJECTHEAL introduces a revolutionary approach with its 4D injectable, self-healing hydrogel, designed to:
- Deliver antibacterial, anti-inflammatory, and pro-angiogenic agents,
- Promote vascularization and tissue regeneration, and
- Provide controlled bioresorption and sustained therapeutic release tailored for deep wounds.
This dynamic platform advances beyond traditional treatments, addressing irregular wound geometries, infection control, and inflammation management. With an interdisciplinary team from leading European institutions, INJECTHEAL is set to transform chronic wound care through industrial readiness and early clinical trials, improving patient outcomes and reducing healthcare burdens globally.
These pivotal projects reflect our commitment to pushing the boundaries of science and innovation in health sciences. We eagerly anticipate the transformative impacts of 4D-REVIVE and INJECTHEAL on global healthcare challenges.